计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
为什么选择此级别
，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC 50 s of 15 nM and 48 nM for EGFR WT and EGFR L858R/T790M , respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy
In Vitro
DBPR112 (compound 78; 0.32-1000 nM; 16 hours) induces reduction of phosphorylated EGFR in a dose-dependent manner. DBPR112 shows the inhibitory activity against HCC827 (CC 50 =25 nM), H1975 (CC 50 =620 nM) and A431 Cell (CC 50 =1.02 μM) cell lines. DBPR112 occupies the ATP-binding site and interacts with surrounding residues by covalent bonding, hydrogen bonds, and hydrophobic interactions, which give it a potent inhibitory activity against WT EGFR. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: H1975 cells Concentration: 0.32, 1.6, 8.0, 40, 200, 1000 nM Incubation Time: 16 hours Result: Induced reduction of phosphorylated EGFR in a dose-dependent manner in H1975 cells.
In Vivo
DBPR112 (orally; 20-50 mg/kg; 5 days/week for 2 consecutive weeks) significantly reduces tumor growth in HCC827 tumor model. DBPR112 (orally; 50 mg/kg; once a day for 15 days) has a significant antitumor effect (mean tumor growth inhibition of 34%) in H1975 tumor model . DBPR112 (IV; 5 mg/kg) has a T 1/2 of 2.3 hours, a CL of 55.6 mL/min•kg, and a V ss of 8.6 L/kg for rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: HCC827 tumor model (6- to 8-week-old athymic NU-Fox1nu nude mice) Dosage: 20, 50 mg/kg Administration: Orally; 5 days/week for 2 consecutive weeks (days 1-5 and 8-12) Result: Significantly reduced tumor growth. Animal Model: Rats Dosage: 5 mg/kg for IV and 20 mg/kg for PO (Pharmacokinetic Analysis) Administration: IV or PO Result: Had a T 1/2 of 2.3 hours, a CL of 55.6 mL/min•kg, and a V ss of 8.6 L/kg by IV. Had a T 1/2 of 3.4 hours, a C max of 508 ng/mL and an AUC of 2978 ng/mL•h by PO.
IC50& Target:EGFR WT 15 nM (IC 50 ) EGFR L858R/T790M 48 nM (IC 50 )
规格
规格或纯度
10mM in DMSO
英文名称
DBPR112
生化机理
DBPR112 是一种口服活性呋喃嘧啶类表皮生长因子受体抑制剂，对表皮生长因子受体 WT 和表皮生长因子受体 L858R/T790M 的 IC 50 s 分别为 15 nM 和 48 nM。DBPR112 可占据 ATP 结合位点。DBPR112 具有显著的抗肿瘤疗效。
储存条件
-80℃储存
运输条件
特低温运输
作用类型
抑制剂
名称和识别符
分子类型
未知
Isomeric SMILES
CN(C)C/C=C/C(=O)NC1=CC=CC(=C1)C2=C(OC3=NC=NC(=C23)N[C@H](CO)C4=CC=CC=C4)C5=CC=CC=C5
PubChem CID
分子量
533.62
技术文档
高级数据
关联靶点（人）
EGFR
Tclin
表皮生长因子受体(Epidermal growth factor receptor)
(3 活性数据)
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）